Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

ConditionsCrohn Disease (CD)Ulcerative Colitis (UC)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age16+

SponsorImelda GI Clinical Research Center

About this trial

Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

≥18 years

Patient with confirmed diagnosis of IBD

Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice

willing to provide informed consent

Disqualifiers

Patient with IBD unspecified

Patient with ileo- or colostomy

Patient with total colectomy

Women that are pregnant

Trial population

patients with IBD

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Leucine-rich α2-glycoprotein
Diagnostic test
Leucine-rich α2-glycoprotein measurement

Treatment groups

100 Participants

are divided into 1 treatment group

Group A: patient with IBD1 intervention

Trial outcomes

Primary outcomes

Correlation between LRG serum level and endoscopic disease activity in CD and UC

Time frame

Day 1

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Imelda GI Clinical Research Center

Lead sponsor

Source ClinicalTrials.gov

Apply now